NYSE:BLCO
Bausch & Lomb Corp
A diversified healthcare provider focused on ophthalmic solutions, medical devices, and prescription drugs facing significant profitability challenges in recent years.
Key Metrics
Investment Thesis
Bull Case
The stock offers an opportunity to acquire a market-leading franchise with robust revenue growth at a distressed valuation, potentially undervalued due to temporary margin compression. Investors may believe that management can successfully delever the $5.02B long-term debt load while restoring profitability through portfolio optimization and new product mix.
Bear Case
Continuing net losses of -$352M and a deepening retained earnings deficit of -$931M suggest fundamental operational issues that have not yet resolved. The company's high leverage and heavy reliance on debt issuances to fund operations create a precarious financial structure that poses significant downside risk in a rising interest rate environment.
About Bausch & Lomb Corp
Bausch Health Limited (BLCO) is a global health company serving patients with eye care products, medical devices, and pharmaceuticals. The company operates primarily in the United States and Europe, leveraging its portfolio of brands to address conditions ranging from refractive errors to chronic diseases.
Analysis
Management Discussion
Despite a 35% revenue increase from $3.77B in 2022 to $5.10B in 2025, the company has struggled with profitability, posting net losses that widened from -$248M in 2023 to -$352M in 2025. Operating cash flow of $283M was insufficient to cover the cumulative capital expenditures and debt repayments, resulting in a significant reduction in cash reserves.
Industry Overview
The healthcare sector is characterized by long development cycles for new drugs, intense competition from generic manufacturers, and strict regulatory oversight regarding pricing and safety. Bausch Health operates in a mature but essential market where patient demand remains inelastic, yet profitability is heavily influenced by reimbursement policies and patent expirations.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $3.77B | $4.15B | $4.79B | $5.10B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $3.77B | $4.15B | $4.79B | $5.10B |
| Operating Expenses | $3.56B | $4.02B | $4.63B | $4.99B |
| Operating Income | $207.0M | $130.0M | $162.0M | $113.0M |
| G&A | $1.48B | $1.74B | $2.08B | $2.23B |
| Stock-Based Comp | $62.0M | $74.0M | $92.0M | $149.0M |
| D&A | $379.0M | $382.0M | $436.0M | $421.0M |
| Depreciation | $135.0M | $142.0M | $148.0M | $163.0M |
| Other OpEx | $2.08B | $2.28B | $2.55B | $2.75B |
| Non-Operating Income | $-134.0M | $-296.0M | $-396.0M | $-430.0M |
| Interest Income | $6.0M | $15.0M | $15.0M | $12.0M |
| Pre-Tax Income | $73.0M | $-166.0M | $-234.0M | $-317.0M |
| Income Tax | $58.0M | $82.0M | $71.0M | $35.0M |
| Continuing Ops | $15.0M | $-248.0M | $-305.0M | $-352.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $15.0M | $-248.0M | $-305.0M | $-352.0M |
| Minority Interest | $9.0M | $12.0M | $12.0M | $8.0M |
| Net to Common | $6.0M | $-260.0M | $-317.0M | $-360.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.14B | $2.74B | $2.79B | $2.98B |
| Cash & Equivalents | $354.0M | $331.0M | $305.0M | $383.0M |
| Inventory | $628.0M | $1.03B | $1.04B | $976.0M |
| Prepaid Expenses | $405.0M | $541.0M | $410.0M | $383.0M |
| Other Current Assets | $750.0M | $842.0M | $1.04B | $1.24B |
| Long-Term Assets | $9.01B | $10.70B | $10.68B | $11.04B |
| PP&E (Net) | $1.30B | $1.39B | $1.49B | $1.76B |
| Intangibles | $2.06B | $3.59B | $3.49B | $3.28B |
| Goodwill | $4.51B | $4.58B | $4.52B | $4.76B |
| Operating Leases | $119.0M | $114.0M | $151.0M | $160.0M |
| Other LT Assets | $1.02B | $1.03B | $1.03B | $1.08B |
| Total Assets | $11.14B | $13.44B | $13.47B | $14.02B |
| Current Liabilities | $1.30B | $1.58B | $1.74B | $1.92B |
| Accounts Payable | $370.0M | $522.0M | $389.0M | $388.0M |
| Current Debt | $25.0M | $30.0M | $40.0M | $28.0M |
| Current Leases | $26.0M | $27.0M | $32.0M | $38.0M |
| Other Current Liab | $-26.0M | $-27.0M | $-32.0M | $-27.0M |
| Long-Term Liabilities | $2.75B | $4.94B | $5.19B | $5.58B |
| Long-Term Debt | $2.41B | $4.53B | $4.74B | $5.02B |
| LT Operating Leases | $92.0M | $87.0M | $120.0M | $125.0M |
| Other LT Liab | $244.0M | $324.0M | $323.0M | $438.0M |
| Total Liabilities | $4.04B | $6.52B | $6.92B | $7.50B |
| Shareholders' Equity | $7.10B | $6.92B | $6.54B | $6.52B |
| Retained Earnings | $6.0M | $-254.0M | $-571.0M | $-931.0M |
| AOCI | $-1.26B | $-1.25B | $-1.39B | $-1.18B |
| Total L&E | $11.14B | $13.44B | $13.47B | $14.02B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $15.0M | $-248.0M | $-305.0M | $-352.0M |
| Non-Cash Adjustments | $-67.0M | $-546.0M | $198.0M | $437.0M |
| Working Capital Changes | $397.0M | $777.0M | $339.0M | $198.0M |
| Cash from Operations | $345.0M | $-17.0M | $232.0M | $283.0M |
| Capital Expenditures | $175.0M | $181.0M | $291.0M | $349.0M |
| Cash from Investing | $-215.0M | $-2.11B | $-412.0M | $-455.0M |
| Debt Issuances | $2.44B | $2.28B | $631.0M | $3.36B |
| Debt Repayments | $13.0M | $161.0M | $430.0M | $3.10B |
| Cash from Financing | $81.0M | $2.08B | $178.0M | $225.0M |
| FX Effect | $-8.0M | $2.0M | $-16.0M | $28.0M |
| Net Change in Cash | $203.0M | $-46.0M | $-18.0M | $81.0M |
| Beginning Cash | $177.0M | $380.0M | $334.0M | $316.0M |
| Ending Cash | $380.0M | $334.0M | $316.0M | $397.0M |
Frequently Asked Questions
How does Bausch & Lomb Corp make money?
The company generates revenue through three main pillars: Ophthalmics (contact lenses, intraocular lenses, and surgical devices), Medical Devices (surgical equipment and diagnostic tools for conditions like sleep apnea and urology), and Pharmaceuticals (prescription medications for respiratory and cardiovascular issues).
What are the main risks for BLCO?
1. Persistent net losses and a growing retained earnings deficit threatening shareholder value and dividend sustainability. 2. High debt levels relative to equity, exacerbated by recent large-scale debt issuances. 3. Vulnerability to regulatory changes in key markets like the US Inflation Reduction Act impacting pricing power. 4. Execution risk on new product launches required to reverse declining profit margins.
What is BLCO's competitive advantage?
1. Extensive portfolio of established brands with strong physician loyalty across multiple therapeutic areas. 2. Global manufacturing footprint allowing for cost efficiencies and supply chain resilience. 3. Deep pipeline of innovative products in high-growth segments like glaucoma treatment and sleep apnea therapy.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.